Long-term Use and Safety of JAK Inhibitors and Evaluating Efficacy Outcomes in Atopic Dermatitis : Episode 9
Pathophysiology of AD Treatments
Andrew Blauvelt, MD, provides an overview of the significance of JAK/Stat pathway inhibition in targeting the pathophysiology of atopic dermatology (AD).
EP: 1.Standard of Care in AD
EP: 2.Clinical Outcomes in AD Clinical Trials
EP: 3.EASI Scores in AD Treatment
EP: 4.NRS in AD Treatment
EP: 5.AD: Efficacy Outcomes
EP: 6.RAD 2023 AD Trial: Meta-Analysis Data
EP: 7.AD Clinical Approach: Switching Therapies
EP: 8.Topical and Systemic Treatments for AD
Now Viewing
EP: 9.Pathophysiology of AD Treatments
EP: 10.Treatment Selection in AD
EP: 11.JAK Inhibitor Safety
EP: 12.AD Treatment: Upadacitinib
EP: 13.Switching Therapies in AD
Related Videos
Related Content
